Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 2:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 359 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DEXA Clear all
Terminated Phase 2 Interventional Results available

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

NCT04251715
View directory record Official record
Conditions
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Intrahepatic Cholangiocarcinoma
Interventions
Dexamethasone, Floxuridine, Implanted Medical Device, Irinotecan, Leucovorin, Oxaliplatin, Quality-of-Life Assessment
Drug · Device · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma

NCT03399539
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, T(11;14)
Interventions
Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Venetoclax
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 21, 2026, 2:37 PM EDT
Terminated Phase 2 Interventional Results available

Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT03256045
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Carfilzomib, Chemosensitivity Assay, Dexamethasone, Laboratory Biomarker Analysis, Panobinostat
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Phase 2 Interventional Results available

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

NCT02828358
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Azacitidine, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin, Daunorubicin Hydrochloride, Dexamethasone, Echocardiography, Hydrocortisone Sodium Succinate, Leucovorin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Multigated Acquisition Scan, Pegaspargase, Prednisolone, Thioguanine, Vincristine, Vincristine Sulfate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 364 Days
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
157
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 128 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 21, 2026, 2:37 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia

NCT02101853
View directory record Official record
Conditions
Recurrent B Acute Lymphoblastic Leukemia
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Asparaginase, Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Leucovorin Calcium, Mercaptopurine, Methotrexate, Mitoxantrone, Mitoxantrone Hydrochloride, Pegaspargase, Pharmacological Study, Radiation Therapy, Therapeutic Hydrocortisone, Thioguanine, Vincristine, Vincristine Sulfate
Procedure · Drug · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 135 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Composition & Function of Sarcoplasmic Reticulum in Persons With the Metabolic Syndrome

NCT02122666
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
muscle biopsy
Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2024 · Synced Oct 21, 2026, 2:37 PM EDT
Recruiting Phase 2 Interventional

Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia

NCT02877303
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Interventions
Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, Vincristine Sulfate
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
14 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

The Impact of Glomerular Disorders on Bone Quality and Strength

NCT04528446
View directory record Official record
Conditions
Glomerular Disease, Bone Diseases, Metabolic, Bone Fracture
Interventions
Dual-energy X-ray absorptiometry, High Resolution Peripheral Quantitative Computed Tomography (HR-pQCT), Blood draw and Urine collection, Questionnaires
Radiation · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 55 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2024 · Synced Oct 21, 2026, 2:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

NCT06785415
View directory record Official record
Conditions
Recurrent Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Elotuzumab, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study

NCT06220396
View directory record Official record
Conditions
Healthy
Interventions
Right Heart Catheterization with Hemodynamics and Limited Echocardiogram, Magnetic Resonance Imaging (MRI), Dual X-ray absorptiometry (DEXA) scan
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation of the Stayhealthy BC1 Body Comp Analyzer

NCT01209923
View directory record Official record
Conditions
Body Composition
Interventions
BC1
Device
Lead sponsor
University of Southern California
Other
Eligibility
10 Years to 80 Years
Enrollment
362 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 21, 2026, 2:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Study Of Biomarkers Of Skeletal Muscle Atrophy

NCT02839460
View directory record Official record
Conditions
Sarcopenia
Interventions
Outpatient Muscle Biopsy
Procedure
Lead sponsor
University of Florida
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 11, 2019 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

NCT01668719
View directory record Official record
Conditions
DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
Interventions
Bortezomib, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide
Drug · Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
417
States / cities
Anchorage, Alaska • Little Rock, Arkansas • Burbank, California + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Not applicable Interventional

Changes in Gut Hormones, Body Composition and Energy Expenditure After Roux-en-Y

NCT02048501
View directory record Official record
Conditions
Obesity, Weight Loss
Interventions
Resting Metabolic Rate (RMR), Duel-energy x-ray absorptiometry (DEXA), Visual Analog Scale (VAS), Meal Stimulation Test
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

NCT01711528
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Bortezomib, Dexamethasone, Dinaciclib, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
6
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Not applicable Interventional Results available

Dexamethasone in Reducing Oral Pain and Dry Mouth After Surgery in Patients With Oropharyngeal Cancer

NCT01748942
View directory record Official record
Conditions
Dysphagia, Pain, Stage I Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Squamous Cell Carcinoma
Interventions
Dexamethasone, Placebo, Quality-of-Life Assessment, Questionnaire Administration, Transoral Robotic Surgery
Drug · Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 19, 2018 · Synced Oct 21, 2026, 2:37 PM EDT
Not listed No phase listed Observational

Radiation Effects on Bone

NCT03134742
View directory record Official record
Conditions
Soft Tissue Sarcoma Adult
Interventions
Control Group, CT Scan, DEXA Scans, CT and DEXA Scans
Other · Diagnostic Test
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

"ADAPT" The Adaptation to High Fat Diets Extention

NCT00493701
View directory record Official record
Conditions
Healthy
Interventions
High Fat Diet, Low Fat Diet
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 30 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 21, 2026, 2:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Brain Health in Midlife

NCT06640842
View directory record Official record
Conditions
Brain Health, Gestational Hypertension, Alzheimer Disease, Dementia, Cardiovascular Diseases, Pregnancy Related, Pre-Eclampsia
Interventions
A combination of various tests and biomarkers will be completed to understand the effect of hypertensive disorders of pregnancy on brain health in midlife.
Diagnostic Test
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 54 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 21, 2026, 2:37 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of Oral Lipid Ingestion in Relation to Ovarian Androgen Secretion in Polycystic Ovary Syndrome (PCOS)

NCT01489319
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Salsalate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma

NCT02697344
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma
Interventions
Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study, R-(-)-Gossypol Acetic Acid
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Phase 4 Interventional Results available

A Type 2 Diabetes Study of the Longer-Term Glycemic Effect of AVANDAMET vs. Metformin

NCT00386100
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Avandamet 6 mg/1500 mg (ttd), Avandamet 4 mg/1000 mg (ttd), Avandamet 2 mg/500 mg (ttd), Avandamet 8 mg/ 2000 mg (ttd), Metformin 500 mg (ttd), Metformin 1000 mg (ttd), Metformin 1500 mg (ttd), Metformin 2000 mg (ttd)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
71
States / cities
Tuscaloosa, Alabama • Gilbert, Arizona • Glendale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 21, 2026, 2:37 PM EDT
Completed Phase 1 Interventional

Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT06203912
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Cyclophosphamide, Dexamethasone, Echocardiography, Isatuximab, Questionnaire Administration, Universal Donor Expanded TGF-beta-imprinted NK Cells
Procedure · Drug · Biological + 1 more
Lead sponsor
Elvira Umyarova
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 2:37 PM EDT